ICMR Transfers Three Indigenous Medical Technologies to Industry at National Technology Day Event
‘Vigyan-Tech’ Programme Showcases India’s Scientific Innovation Across 14 Ministries
Union Minister of State for Science and Technology Dr Jitendra Singh inaugurated the national technology exhibition and interacted with innovators, scientists, and exhibitors participating in the programme.
New Delhi: Indian Council of Medical Research (ICMR) on Monday transferred three indigenous medical technologies to industry partners through licensing agreements during the National Technology Day 2026 programme ‘विज्ञान–Tech’, reinforcing the Centre’s push toward innovation-led healthcare and indigenous medical technology development.
The national event, organised at the National Institute of Immunology (NII) here, was coordinated by the Office of the Principal Scientific Adviser in collaboration with the Department of Biotechnology (DBT) and brought together 14 scientific ministries and departments to showcase India’s scientific and technological advancements.
Union Minister of State for Science and Technology Dr Jitendra Singh inaugurated the national technology exhibition and interacted with innovators, scientists, and exhibitors participating in the programme.
Principal Scientific Adviser to the Government of India Ajay Kumar Sood and Secretary, Department of Health Research and Director General of ICMR Rajiv Bahl were also present during the event.
As part of the exhibition, ICMR showcased six major indigenous technologies across the biopharma, healthcare, and bioindustrial sectors including Covaxin, the COVID Kavach ELISA Kit, a CRISPR-Cas-based tuberculosis detection system, a Nipah point-of-care assay, a dengue diagnostic ELISA kit, and a mosquito-control biolarvicide.
ICMR also featured 25 additional innovations developed by its research institutes in areas including diagnostics, digital health, disease surveillance, medical devices, and translational research.
A key highlight of the programme was the signing of licensing agreements for three ICMR-developed technologies under the Medical Innovations Patent Mitra initiative aimed at commercialising publicly funded medical innovations.
The first licensed technology — a cost-effective PSP94 ELISA test designed to guide prostate biopsy decisions in patients with PSA levels below 20 ng/ml — was developed by scientists at ICMR-National Institute for Research in Women’s Health and licensed to Krishgen Labs Pvt. Ltd..
The second technology involved a point-of-care diagnostic solution for Factor VIII inhibitor and coagulation disorders developed at ICMR-National Institute for Research on Blood and Immune Disorders and licensed to Meril Life Sciences.
The third technology — a single-tube multiplex real-time RT-PCR platform for simultaneous detection of dengue, chikungunya, and Zika viruses — was developed at ICMR-National Institute of Virology and licensed to Vanguard Life Sciences.
Officials said the technology transfer initiative reflects ICMR’s strategy of protecting publicly funded research through structured intellectual property support while accelerating commercialisation and industry adoption.
The initiative is also aligned with the government’s “Make in Bharat” vision aimed at strengthening indigenous manufacturing capabilities, reducing import dependence, and building a self-reliant healthcare ecosystem.
The ‘विज्ञान–Tech’ programme served as a national platform for promoting collaboration among government agencies, academia, research institutions, and industry stakeholders in support of India’s broader “Viksit Bharat” vision.
